Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
 Blood, 1 April 2005, Vol. 105, No. 7, pp. 2640-2653.
Prepublished online as a Blood First Edition Paper on December 23, 2004; DOI 10.1182/blood-2004-08-3097.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
2004-08-3097v1
105/7/2640    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Deininger, M.
Right arrow Articles by Druker, B. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Deininger, M.
Right arrow Articles by Druker, B. J.
Related Collections
Right arrow Neoplasia
Right arrow Oncogenes and Tumor Suppressors
Right arrow Signal Transduction
Right arrow Reviews in Translational Hematology
Right arrow Free Research Articles
Right arrow Clinical Trials and Observations
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

REVIEW IN TRANSLATIONAL HEMATOLOGY

The development of imatinib as a therapeutic agent for chronic myeloid leukemia

Michael Deininger, Elisabeth Buchdunger, and Brian J. Druker

From the Oregon Health & Science University Cancer Institute, Portland, OR; Novartis Institutes for Biomedical Research, Novartis Pharma, Basel, Switzerland; and Howard Hughes Medical Institute, Chevy Chase, MD.

Abstract

Imatinib has revolutionized drug therapy of chronic myeloid leukemia (CML). Preclinical studies were promising but the results of clinical trials by far exceeded expectations. Responses in chronic phase are unprecedented, with rates of complete cytogenetic response (CCR) of more than 40% in patients after failure of interferon-{alpha} (IFN) and more than 80% in newly diagnosed patients, a level of efficacy that led to regulatory approval in record time. While most of these responses are stable, resistance to treatment after an initial response is common in more advanced phases of the disease. Mutations in the kinase domain (KD) of BCR-ABL that impair imatinib binding have been identified as the leading cause of resistance. Patients with CCR who achieve a profound reduction of BCR-ABL mRNA have a very low risk of disease progression. However, residual disease usually remains detectable with reverse transcription–polymerase chain reaction (RT-PCR), indicating that disease eradication may pose a significant challenge. The mechanisms underlying the persistence of minimal residual disease are unknown. In this manuscript, we review the preclinical and clinical development of imatinib for the therapy of CML, resistance and strategies that may help to eliminate resistant or residual leukemia.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
A. Quintas-Cardama and J. Cortes
Therapeutic Options Against BCR-ABL1 T315I-Positive Chronic Myelogenous Leukemia
Clin. Cancer Res., July 15, 2008; 14(14): 4392 - 4399.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. Ostermann, P. Garin-Chesa, K. H. Heider, M. Kalat, H. Lamche, C. Puri, D. Kerjaschki, W. J. Rettig, and G. R. Adolf
Effective Immunoconjugate Therapy in Cancer Models Targeting a Serine Protease of Tumor Fibroblasts
Clin. Cancer Res., July 15, 2008; 14(14): 4584 - 4592.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. W. Deininger
Nilotinib
Clin. Cancer Res., July 1, 2008; 14(13): 4027 - 4031.
[Full Text] [PDF]

Home page
 Cardiovasc ResHome page
C. Leipner, K. Grun, A. Muller, E. Buchdunger, L. Borsi, H. Kosmehl, A. Berndt, T. Janik, A. Uecker, M. Kiehntopf, et al.
Imatinib mesylate attenuates fibrosis in coxsackievirus b3-induced chronic myocarditis
Cardiovasc Res, July 1, 2008; 79(1): 118 - 126.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Verstovsek, A. Tefferi, J. Cortes, S. O'Brien, G. Garcia-Manero, A. Pardanani, C. Akin, S. Faderl, T. Manshouri, D. Thomas, et al.
Phase II Study of Dasatinib in Philadelphia Chromosome-Negative Acute and Chronic Myeloid Diseases, Including Systemic Mastocytosis
Clin. Cancer Res., June 15, 2008; 14(12): 3906 - 3915.
[Abstract] [Full Text] [PDF]

Home page
 Genes Dev.Home page
C. G. Mullighan, R. T. Williams, J. R. Downing, and C. J. Sherr
Failure of CDKN2A/B (INK4A/B-ARF)-mediated tumor suppression and resistance to targeted therapy in acute lymphoblastic leukemia induced by BCR-ABL
Genes & Dev., June 1, 2008; 22(11): 1411 - 1415.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. ProteomicsHome page
A. Pierce, R. D. Unwin, C. A. Evans, S. Griffiths, L. Carney, L. Zhang, E. Jaworska, C.-F. Lee, D. Blinco, M. J. Okoniewski, et al.
Eight-channel iTRAQ Enables Comparison of the Activity of Six Leukemogenic Tyrosine Kinases
Mol. Cell. Proteomics, May 1, 2008; 7(5): 853 - 863.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
M. Puttini, S. Redaelli, L. Moretti, S. Brussolo, R. H Gunby, L. Mologni, E. Marchesi, L. Cleris, A. Donella-Deana, P. Drueckes, et al.
Characterization of compound 584, an Abl kinase inhibitor with lasting effects
Haematologica, May 1, 2008; 93(5): 653 - 661.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
E. Sala, L. Mologni, S. Truffa, C. Gaetano, G. E. Bollag, and C. Gambacorti-Passerini
BRAF Silencing by Short Hairpin RNA or Chemical Blockade by PLX4032 Leads to Different Responses in Melanoma and Thyroid Carcinoma Cells
Mol. Cancer Res., May 1, 2008; 6(5): 751 - 759.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Gontarewicz, S. Balabanov, G. Keller, R. Colombo, A. Graziano, E. Pesenti, D. Benten, C. Bokemeyer, W. Fiedler, J. Moll, et al.
Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I
Blood, April 15, 2008; 111(8): 4355 - 4364.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
P. Ramirez and J. F. DiPersio
Therapy Options in Imatinib Failures
Oncologist, April 1, 2008; 13(4): 424 - 434.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
C. Roche-Lestienne, L. Deluche, S. Corm, I. Tigaud, S. Joha, N. Philippe, S. Geffroy, J.-L. Lai, F.-E. Nicolini, C. Preudhomme, et al.
RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance
Blood, April 1, 2008; 111(7): 3735 - 3741.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
N. Carayol, E. Katsoulidis, A. Sassano, J. K. Altman, B. J. Druker, and L. C. Platanias
Suppression of Programmed Cell Death 4 (PDCD4) Protein Expression by BCR-ABL-regulated Engagement of the mTOR/p70 S6 Kinase Pathway
J. Biol. Chem., March 28, 2008; 283(13): 8601 - 8610.
[Abstract] [Full Text] [PDF]

Home page
 J. Mol. Diagn.Home page
J. Laudadio, M. W.N. Deininger, M. J. Mauro, B. J. Druker, and R. D. Press
An Intron-Derived Insertion/Truncation Mutation in the BCR-ABL Kinase Domain in Chronic Myeloid Leukemia Patients Undergoing Kinase Inhibitor Therapy
J. Mol. Diagn., March 1, 2008; 10(2): 177 - 180.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
H. Konig, T. L. Holyoake, and R. Bhatia
Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase inhibitor SKI-606
Blood, February 15, 2008; 111(4): 2329 - 2338.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. K. Ramanathan, M. J. Egorin, C. H.M. Takimoto, S. C. Remick, J. H. Doroshow, P. A. LoRusso, D. L. Mulkerin, J. L. Grem, A. Hamilton, A. J. Murgo, et al.
Phase I and Pharmacokinetic Study of Imatinib Mesylate in Patients With Advanced Malignancies and Varying Degrees of Liver Dysfunction: A Study by the National Cancer Institute Organ Dysfunction Working Group
J. Clin. Oncol., February 1, 2008; 26(4): 563 - 569.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Biol. CellHome page
T. L. Stevens, E. M. Rogers, L. M. Koontz, D. T. Fox, C. C.F. Homem, S. H. Nowotarski, N. B. Artabazon, and M. Peifer
Using Bcr-Abl to Examine Mechanisms by Which Abl Kinase Regulates Morphogenesis in Drosophila
Mol. Biol. Cell, January 1, 2008; 19(1): 378 - 393.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
J. McLaughlin, D. Cheng, O. Singer, R. U. Lukacs, C. G. Radu, I. M. Verma, and O. N. Witte
Sustained suppression of Bcr-Abl-driven lymphoid leukemia by microRNA mimics
PNAS, December 18, 2007; 104(51): 20501 - 20506.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. Kawano, M. Ito, D. Raina, Z. Wu, J. Rosenblatt, D. Avigan, R. Stone, and D. Kufe
MUC1 Oncoprotein Regulates Bcr-Abl Stability and Pathogenesis in Chronic Myelogenous Leukemia Cells
Cancer Res., December 15, 2007; 67(24): 11576 - 11584.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
J. G. Christensen, H. Y. Zou, M. E. Arango, Q. Li, J. H. Lee, S. R. McDonnell, S. Yamazaki, G. R. Alton, B. Mroczkowski, and G. Los
Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma
Mol. Cancer Ther., December 1, 2007; 6(12): 3314 - 3322.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
C. E. de Kogel and J. H. M. Schellens
Imatinib
Oncologist, December 1, 2007; 12(12): 1390 - 1394.
[Full Text] [PDF]

Home page
 BloodHome page
A. Chase, F. H. Grand, and N. C. P. Cross
Activity of TKI258 against primary cells and cell lines with FGFR1 fusion genes associated with the 8p11 myeloproliferative syndrome
Blood, November 15, 2007; 110(10): 3729 - 3734.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. M. Goldman
How I treat chronic myeloid leukemia in the imatinib era
Blood, October 15, 2007; 110(8): 2828 - 2837.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. L. Kwak, J. W. Clark, and B. Chabner
Targeted Agents: The Rules of Combination
Clin. Cancer Res., September 15, 2007; 13(18): 5232 - 5237.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
T. Raz, V. Nardi, M. Azam, J. Cortes, and G. Q. Daley
Farnesyl transferase inhibitor resistance probed by target mutagenesis
Blood, September 15, 2007; 110(6): 2102 - 2109.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Quintas-Cardama, H. Kantarjian, S. O'Brien, G. Borthakur, J. Bruzzi, R. Munden, and J. Cortes
Pleural Effusion in Patients With Chronic Myelogenous Leukemia Treated With Dasatinib After Imatinib Failure
J. Clin. Oncol., September 1, 2007; 25(25): 3908 - 3914.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Modugno, E. Casale, C. Soncini, P. Rosettani, R. Colombo, R. Lupi, L. Rusconi, D. Fancelli, P. Carpinelli, A. D. Cameron, et al.
Crystal Structure of the T315I Abl Mutant in Complex with the Aurora Kinases Inhibitor PHA-739358
Cancer Res., September 1, 2007; 67(17): 7987 - 7990.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
E. S. Winn-Deen, B. Helton, R. Van Atta, W. Wong, J. Peralta, J. Wang, G. J. Tsongalis, D. Belloni, D. Chan, J. R. Eshleman, et al.
Development of an Integrated Assay for Detection of BCR-ABL RNA
Clin. Chem., September 1, 2007; 53(9): 1593 - 1600.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
O. Hantschel, U. Rix, U. Schmidt, T. Burckstummer, M. Kneidinger, G. Schutze, J. Colinge, K. L. Bennett, W. Ellmeier, P. Valent, et al.
The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib
PNAS, August 14, 2007; 104(33): 13283 - 13288.
[Abstract] [Full Text] [PDF]

Home page
 BioinformaticsHome page
G. M. Verkhivker
Exploring sequence-structure relationships in the tyrosine kinome space: functional classification of the binding specificity mechanisms for cancer therapeutics
Bioinformatics, August 1, 2007; 23(15): 1919 - 1926.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
H. Vikis, M. Sato, M. James, D. Wang, Y. Wang, M. Wang, D. Jia, Y. Liu, J. E. Bailey-Wilson, C. I. Amos, et al.
EGFR-T790M Is a Rare Lung Cancer Susceptibility Allele with Enhanced Kinase Activity
Cancer Res., May 15, 2007; 67(10): 4665 - 4670.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
X. Jiang, K. M. Saw, A. Eaves, and C. Eaves
Instability of BCR-ABL Gene in Primary and Cultured Chronic Myeloid Leukemia Stem Cells
J Natl Cancer Inst, May 2, 2007; 99(9): 680 - 693.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
T. K. Nguyen, M. Rahmani, H. Harada, P. Dent, and S. Grant
MEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the dual Abl/Src inhibitor BMS-354/825
Blood, May 1, 2007; 109(9): 4006 - 4015.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J.-Y. Blay, A. Le Cesne, I. Ray-Coquard, B. Bui, F. Duffaud, C. Delbaldo, A. Adenis, P. Viens, M. Rios, E. Bompas, et al.
Prospective Multicentric Randomized Phase III Study of Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors Comparing Interruption Versus Continuation of Treatment Beyond 1 Year: The French Sarcoma Group
J. Clin. Oncol., March 20, 2007; 25(9): 1107 - 1113.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Hochhaus, H. M. Kantarjian, M. Baccarani, J. H. Lipton, J. F. Apperley, B. J. Druker, T. Facon, S. L. Goldberg, F. Cervantes, D. Niederwieser, et al.
Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy
Blood, March 15, 2007; 109(6): 2303 - 2309.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
C. Miething, R. Grundler, C. Mugler, S. Brero, J. Hoepfl, J. Geigl, M. R. Speicher, O. Ottmann, C. Peschel, and J. Duyster
Retroviral insertional mutagenesis identifies RUNX genes involved in chronic myeloid leukemia disease persistence under imatinib treatment
PNAS, March 13, 2007; 104(11): 4594 - 4599.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
J. Roman-Gomez, A. Jimenez-Velasco, X. Agirre, J. A. Castillejo, G. Navarro, E. San Jose-Eneriz, L. Garate, L. Cordeu, F. Cervantes, F. Prosper, et al.
Epigenetic regulation of human cancer/testis antigen gene, HAGE, in chronic myeloid leukemia
Haematologica, February 1, 2007; 92(2): 153 - 162.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
C. Yoshida, F. Yoshida, D. E. Sears, S. M. Hart, D. Ikebe, A. Muto, S. Basu, K. Igarashi, and J. V. Melo
Bcr-Abl signaling through the PI-3/S6 kinase pathway inhibits nuclear translocation of the transcription factor Bach2, which represses the antiapoptotic factor heme oxygenase-1
Blood, February 1, 2007; 109(3): 1211 - 1219.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Quintas-Cardama, H. Kantarjian, D. Jones, C. Nicaise, S. O'Brien, F. Giles, M. Talpaz, and J. Cortes
Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure
Blood, January 15, 2007; 109(2): 497 - 499.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
E. Lierman, I. Lahortiga, H. Van Miegroet, N. Mentens, P. Marynen, and J. Cools
The ability of sorafenib to inhibit oncogenic PDGFR{beta} and FLT3 mutants and overcome resistance to other small molecule inhibitors
Haematologica, January 1, 2007; 92(1): 27 - 34.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Baranowska-Kortylewicz, M. Abe, J. Nearman, and C. A. Enke
Emerging